TSANZ SIG Orals: Orphan Lung Diseases, Lung Transplant, Interstitial Lung Disease and Pulmonary Vascular Disease (OLIV) 2
Tracks
TSANZ Orals
Sunday, March 23, 2025 |
1:00 PM - 2:30 PM |
E3 |
Speaker
Dr Pamela Karas
Advanced Trainee
Royal Prince Alfred Hospital
The use of antifibrotics in non-idiopathic pulmonary fibrosis: a descriptive cohort study of participants in the Australasian interstitial lung disease registry
1:00 PM - 1:15 PMBiography
Pamela is an Advanced Trainee who previously worked within the ILD MDT at Royal Prince Alfred Hosptial. She has an interest in advanced lung disease and is currently the Clinical Research Lung Transplant Fellow at St Vincent's Hospital, Darlinghurst.
Dr John Mackintosh
Respiratory Physician
The Prince Charles Hospital
Combined deep learning algorithms demonstrate that both computed tomography phenotype and anatomical biomarkers are predictive of prognosis and progression in idiopathic pulmonary fibrosis
1:15 PM - 1:30 PMBiography
John is a respiratory physician at The Prince Charles Hospital, Brisbane. John completed a clinical fellowship in interstitial lung disease in 2018 at The Royal Brompton Hospital, London. John provides a dedicated interstitial lung disease outpatient service and is co- chair of the Queensland Statewide Interstitial Lung Disease Multi-Disciplinary Meeting.
Dr John Mackintosh
Respiratory Physician
The Prince Charles Hospital
Deep learning quantitative computed tomography analysis in the Australian idiopathic pulmonary fibrosis registry
1:30 PM - 1:45 PMBiography
John is a respiratory physician at The Prince Charles Hospital, Brisbane. John completed a clinical fellowship in interstitial lung disease in 2018 at The Royal Brompton Hospital, London. John provides a dedicated interstitial lung disease outpatient service and is co- chair of the Queensland Statewide Interstitial Lung Disease Multi-Disciplinary Meeting.
Miss Emma Marshall
Research Assistant
Institute for Breathing and Sleep
Geographical disparities for phase II/III pharmaceutical randomised controlled trials in Interstitial lung disease
1:45 PM - 2:00 PMBiography
Emma Marshall is a research assistant at the Institute for Breathing and Sleep, she has an ongoing interest in research in respiratory and sleep medicine. Particularly with an interest in improving quality of life for patients with lung diseases and sleep disorders.
Dr Claire McLaughlin
Respiratory Advanced Trainee
Fiona Stanley Hospital
Australasian interstitial lung disease patients in 2024- a registry study
2:00 PM - 2:15 PMBiography
Dr Claire Mclaughlin is a Respiratory Advanced Trainee currently working at Fiona Stanley Hospital at the time of submission. She has a keen interest in all thing's lungs but particularly Interstitial lung diseases, airways and pleural medicine.
Dr Ling-Ling Tsai
Post-doctoral Research Fellowship
University of Sydney
Diagnostic agreement between interstitial lung disease multidisciplinary-meetings: A bi-national study
2:15 PM - 2:30 PMBiography
Dr Ling-Ling Tsai is a post-doctoral fellow at the Centre of Research Excellence in Pulmonary Fibrosis, Australia. She was awarded a Doctor of Philosophy (Clinical Rehabilitation) degree from the University of Sydney in 2019. Dr Tsai's is also an active clinician-researcher specialising in pulmonary rehabilitation at RPAH, Sydney, Australia
Dr Ingrid Cox
Postdoctoral Research Fellow
Menzies Institute for Medical Research
Chairperson
Biography
Prof Yuben Moodley
Professor
University of Western Australia
Chairperson
Biography
Professor Yuben Moodley is the head of the Cell Biology at the Institute for Respiratory Health, a Consultant Respiratory Physician at Fiona Stanley Hospital and Professor of Respiratory Medicine at the University of Western Australia.
His research interests include finding biomarkers for disease prognosis and response and investigating the pathogenesis of interstitial lung diseases. Furthermore, his team are examining the of epigenetics in lung diseases and the optimization of patient care by focusing on treatable traits. They are using stem cells and organoids to model chronic lung diseases and are presently developing new treatment targets in Idiopathic Pulmonary Fibrosis.
